Furkan Sarici

554 total citations
28 papers, 391 citations indexed

About

Furkan Sarici is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Furkan Sarici has authored 28 papers receiving a total of 391 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 12 papers in Cancer Research and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Furkan Sarici's work include Breast Cancer Treatment Studies (10 papers), HER2/EGFR in Cancer Research (9 papers) and Cancer Treatment and Pharmacology (7 papers). Furkan Sarici is often cited by papers focused on Breast Cancer Treatment Studies (10 papers), HER2/EGFR in Cancer Research (9 papers) and Cancer Treatment and Pharmacology (7 papers). Furkan Sarici collaborates with scholars based in Türkiye, United Kingdom and India. Furkan Sarici's co-authors include Kadri Altundağ, Taner Babacan, Neyran Kertmen, Özge Keskin, İbrahim Petekkaya, Mustafa Solak, Fatma Paksoy Türköz, Zafer Arık, Yavuz Özışık and Serkan Akın and has published in prestigious journals such as Journal of Clinical Oncology, The Breast and SpringerPlus.

In The Last Decade

Furkan Sarici

25 papers receiving 380 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Furkan Sarici Türkiye	10	263	150	93	78	59	28	391
Nicoletta Provinciali Italy	9	175 0.7×	119 0.8×	83 0.9×	54 0.7×	48 0.8×	22	308
Lorraine Durcan United Kingdom	9	310 1.2×	281 1.9×	94 1.0×	83 1.1×	121 2.1×	10	454
Janine Lombard Australia	11	204 0.8×	78 0.5×	88 0.9×	64 0.8×	55 0.9×	38	395
Salma Butt Sweden	12	203 0.8×	145 1.0×	90 1.0×	41 0.5×	100 1.7×	21	417
Kenji Higaki Japan	11	200 0.8×	159 1.1×	57 0.6×	98 1.3×	68 1.2×	39	363
Sebastian Lundgren Sweden	10	389 1.5×	94 0.6×	71 0.8×	104 1.3×	82 1.4×	21	541
Ana Elisa Lohmann Canada	11	240 0.9×	92 0.6×	167 1.8×	57 0.7×	19 0.3×	27	397
Neil Majithia United States	12	398 1.5×	83 0.6×	159 1.7×	58 0.7×	53 0.9×	19	565
Liang Zhuang China	12	144 0.5×	93 0.6×	188 2.0×	55 0.7×	29 0.5×	28	398
Yolanda Jerez Spain	12	297 1.1×	105 0.7×	123 1.3×	83 1.1×	53 0.9×	30	433

Countries citing papers authored by Furkan Sarici

Since Specialization

Citations

This map shows the geographic impact of Furkan Sarici's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Furkan Sarici with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Furkan Sarici more than expected).

Fields of papers citing papers by Furkan Sarici

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Furkan Sarici. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Furkan Sarici. The network helps show where Furkan Sarici may publish in the future.

Co-authorship network of co-authors of Furkan Sarici

This figure shows the co-authorship network connecting the top 25 collaborators of Furkan Sarici. A scholar is included among the top collaborators of Furkan Sarici based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Furkan Sarici. Furkan Sarici is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sarici, Furkan & Kadri Altundağ. (2021). Efficacy and safety evaluation of eribulin-trastuzumab combination therapy with heavily pretreated HER2-positive metastatic breast cancer.. PubMed. 25(6). 2562–2569.

Sarici, Furkan, Taner Babacan, Hakan Büyükhatipoğlu, et al.. (2017). Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience.. PubMed. 21(4). 826–831.

Ateş, Öztürk, Taner Babacan, Neyran Kertmen, et al.. (2016). Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.. PubMed. 21(2). 375–81. 7 indexed citations

Yazıcı, Haşmet, et al.. (2016). Protective Effect of Selenium Against Cisplatin-Induced Ototoxicity in an Experimental Design. Journal of Craniofacial Surgery. 27(7). e610–e614. 7 indexed citations

Ateş, Öztürk, Taner Babacan, Furkan Sarici, et al.. (2016). Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors. SpringerPlus. 5(1). 486–486. 25 indexed citations

Babacan, Taner, Orhan Efe, Hakan Büyükhatipoğlu, et al.. (2015). Efficacy of Capecitabine Monotherapy as the First-line Treatment of Metastatic HER2-negative Breast Cancer. Tumori Journal. 101(4). 418–423. 8 indexed citations

Kertmen, Neyran, Sercan Aksoy, Mustafa Cengiz, et al.. (2015). Comparison of Three Different Induction Regimens for Nasopharyngeal Cancer. Asian Pacific Journal of Cancer Prevention. 16(1). 59–63. 2 indexed citations

Büyükhatipoğlu, Hakan, Taner Babacan, Neyran Kertmen, et al.. (2015). A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer.. PubMed. 20(1). 22–7. 5 indexed citations

Kertmen, Neyran, Taner Babacan, Özge Keskin, et al.. (2015). Molecular subtypes in patients with inflammatory breast cancer; a single center experience.. PubMed. 20(1). 35–9. 16 indexed citations

10.

Babacan, Taner, Hakan Büyükhatipoğlu, Neyran Kertmen, et al.. (2015). Chemotherapy might not be beneficial in lymph node- negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis.. PubMed. 20(2). 479–86. 2 indexed citations

11.

Babacan, Taner, et al.. (2015). The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+ breast cancer patients.. PubMed. 20(1). 50–6. 11 indexed citations

12.

Kertmen, Neyran, Sercan Aksoy, Ayşegül Üner, et al.. (2015). Which sequence best protects the heart against trastuzumab and anthracycline toxicity? An electron microscopy study in rats.. PubMed. 35(2). 857–64. 7 indexed citations

13.

Keskin, Özge, Sercan Aksoy, Taner Babacan, et al.. (2014). Impact of the obesity on lymph node status in operable breast cancer patients.. PubMed. 18(4). 824–30. 9 indexed citations

14.

Türköz, Fatma Paksoy, Mustafa Solak, İbrahim Petekkaya, et al.. (2013). The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women.. PubMed. 18(2). 335–41. 55 indexed citations

15.

Babacan, Taner, et al.. (2013). Adult Langerhans' cell histiocytosis: a rare cause of parotid gland enlargement.. PubMed. 18(2). 546–7. 3 indexed citations

16.

Babacan, Taner, et al.. (2013). Safety of Tamoxifen During Pregnancy: 3 Case Reports and Review of the Literature. Breast Care. 8(6). 453–454. 11 indexed citations

17.

Türköz, Fatma Paksoy, Mustafa Solak, Sercan Aksoy, et al.. (2013). Association between family history and clinicopathologic characteristics in 1987 breast cancer patients: single institution experience from Turkey.. PubMed. 17(4). 649–57. 3 indexed citations

18.

Babacan, Taner, et al.. (2013). Granulocyte colony stimulating factor-induced tumor lysis-like syndrome: leucolysis.. PubMed. 18(2). 549–50. 1 indexed citations

19.

Sarici, Furkan, et al.. (2013). Colon involvement in a chronic lymphocytic leukemia patient.. PubMed. 18(1). 291–2. 1 indexed citations

20.

Türköz, Fatma Paksoy, Mustafa Solak, İbrahim Petekkaya, et al.. (2012). Association between common risk factors and molecular subtypes in breast cancer patients. The Breast. 22(3). 344–350. 130 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact